| pubmed-article:8054909 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8054909 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:8054909 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:8054909 | lifeskim:mentions | umls-concept:C0005961 | lld:lifeskim |
| pubmed-article:8054909 | lifeskim:mentions | umls-concept:C0439849 | lld:lifeskim |
| pubmed-article:8054909 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
| pubmed-article:8054909 | lifeskim:mentions | umls-concept:C0856825 | lld:lifeskim |
| pubmed-article:8054909 | lifeskim:mentions | umls-concept:C0445223 | lld:lifeskim |
| pubmed-article:8054909 | lifeskim:mentions | umls-concept:C1552599 | lld:lifeskim |
| pubmed-article:8054909 | lifeskim:mentions | umls-concept:C1514756 | lld:lifeskim |
| pubmed-article:8054909 | lifeskim:mentions | umls-concept:C1704787 | lld:lifeskim |
| pubmed-article:8054909 | lifeskim:mentions | umls-concept:C1708943 | lld:lifeskim |
| pubmed-article:8054909 | lifeskim:mentions | umls-concept:C0288048 | lld:lifeskim |
| pubmed-article:8054909 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:8054909 | pubmed:dateCreated | 1994-9-9 | lld:pubmed |
| pubmed-article:8054909 | pubmed:abstractText | Fifteen children with steroid-resistant acute graft-versus-host disease (GVHD, grade II-IV) were treated with a murine monoclonal antibody (BT 563) specific for the alpha subunit of the interleukin-2 receptor (IL-2R). All had inherited diseases of the bone marrow and had received T cell-depleted marrow from a partially matched related donor. BT 563 antibody was given at a daily dose of 0.2 mg/kg. Treatment was continued until GVHD was controlled and the methylprednisolone administration was tapered to < or = 2 mg/kg/day. No side-effects were noted. Eleven of the 15 patients reached complete remission and a partial remission occurred in two. This good response rate was associated with early treatment (mean time after GVHD onset 7.7 +/- 5.3 days) and prolonged treatment (mean 25.9 +/- 10.6 days) compared with previously published data on BT 563 antibody usage. Relapses occurred in six of the 13 responders but a further remission was induced by the same treatment. Chronic GVHD developed in six cases and one of them died of GVHD-associated infection. Ten of the 15 patients are long-term survivors and are free of chronic GVHD. The results of this pilot study indicate that early and lengthy treatment with anti-IL-2R monoclonal antibody is both safe and effective against steroid-resistant GVHD in young children and indicate that further trials of anti-IL-2R antibody as first-line therapy of acute GVHD are warranted. | lld:pubmed |
| pubmed-article:8054909 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8054909 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8054909 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8054909 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8054909 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8054909 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8054909 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8054909 | pubmed:month | May | lld:pubmed |
| pubmed-article:8054909 | pubmed:issn | 0268-3369 | lld:pubmed |
| pubmed-article:8054909 | pubmed:author | pubmed-author:WijdenesJJ | lld:pubmed |
| pubmed-article:8054909 | pubmed:author | pubmed-author:FischerAA | lld:pubmed |
| pubmed-article:8054909 | pubmed:author | pubmed-author:RacadotEE | lld:pubmed |
| pubmed-article:8054909 | pubmed:author | pubmed-author:StephanJ LJL | lld:pubmed |
| pubmed-article:8054909 | pubmed:author | pubmed-author:Le DeistFF | lld:pubmed |
| pubmed-article:8054909 | pubmed:author | pubmed-author:DonadieuJJ | lld:pubmed |
| pubmed-article:8054909 | pubmed:author | pubmed-author:HerbelinCC | lld:pubmed |
| pubmed-article:8054909 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8054909 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:8054909 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8054909 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8054909 | pubmed:pagination | 563-9 | lld:pubmed |
| pubmed-article:8054909 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8054909 | pubmed:meshHeading | pubmed-meshheading:8054909-... | lld:pubmed |
| pubmed-article:8054909 | pubmed:meshHeading | pubmed-meshheading:8054909-... | lld:pubmed |
| pubmed-article:8054909 | pubmed:meshHeading | pubmed-meshheading:8054909-... | lld:pubmed |
| pubmed-article:8054909 | pubmed:meshHeading | pubmed-meshheading:8054909-... | lld:pubmed |
| pubmed-article:8054909 | pubmed:meshHeading | pubmed-meshheading:8054909-... | lld:pubmed |
| pubmed-article:8054909 | pubmed:meshHeading | pubmed-meshheading:8054909-... | lld:pubmed |
| pubmed-article:8054909 | pubmed:meshHeading | pubmed-meshheading:8054909-... | lld:pubmed |
| pubmed-article:8054909 | pubmed:meshHeading | pubmed-meshheading:8054909-... | lld:pubmed |
| pubmed-article:8054909 | pubmed:meshHeading | pubmed-meshheading:8054909-... | lld:pubmed |
| pubmed-article:8054909 | pubmed:meshHeading | pubmed-meshheading:8054909-... | lld:pubmed |
| pubmed-article:8054909 | pubmed:meshHeading | pubmed-meshheading:8054909-... | lld:pubmed |
| pubmed-article:8054909 | pubmed:meshHeading | pubmed-meshheading:8054909-... | lld:pubmed |
| pubmed-article:8054909 | pubmed:meshHeading | pubmed-meshheading:8054909-... | lld:pubmed |
| pubmed-article:8054909 | pubmed:meshHeading | pubmed-meshheading:8054909-... | lld:pubmed |
| pubmed-article:8054909 | pubmed:meshHeading | pubmed-meshheading:8054909-... | lld:pubmed |
| pubmed-article:8054909 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8054909 | pubmed:articleTitle | Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants. | lld:pubmed |
| pubmed-article:8054909 | pubmed:affiliation | Département de Pédiatrie, Hôpital des Enfants Malades, Paris, France. | lld:pubmed |
| pubmed-article:8054909 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8054909 | lld:pubmed |
